Business Description
Amylyx Pharmaceuticals is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for rare neurological and hormonal disorders. Its pipeline includes several investigational medicines at various stages of clinical testing, targeting conditions such as ALS, Wolfram syndrome, progressive supranuclear palsy, and post-bariatric hypoglycemia. A key area of focus involves GLP-1 receptor antagonists, a novel class of compounds being studied across multiple rare diseases. Founded in 2013, the company has not yet brought a product to market in the United States.
